ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Blueprint Medicines Corporation Investors to Inquire About Class Action Investigation - BPMCNewsfile Corp • 09/03/22
Blueprint Medicines (BPMC) Up 22.7% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 09/01/22
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Blueprint Medicines Corporation Investors to Inquire About Class Action Investigation - BPMCPRNewsWire • 08/29/22
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the FirmNewsfile Corp • 08/24/22
CANCER Publishes Study Demonstrating Substantial Disease Burden for Patients with Systemic MastocytosisPRNewsWire • 08/24/22
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the FirmNewsfile Corp • 08/23/22
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the FirmNewsfile Corp • 08/22/22
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the FirmNewsfile Corp • 08/19/22
EQUITY ALERT: Rosen Law Firm Encourages Blueprint Medicines Corporation Investors to Inquire About Class Action Investigation – BPMCBusiness Wire • 08/17/22
Blueprint Medicines Stock Hammered As 'Long-Awaited' Test Results DisappointInvestors Business Daily • 08/17/22
Blueprint's stock falls 11% after sharing new Phase 2 data for its rare-disease therapyMarket Watch • 08/17/22
Blueprint Medicines Announces Positive Top-line Results from PIONEER Trial of AYVAKIT® (avapritinib) in Patients with Non-Advanced Systemic Mastocytosis Achieving Primary and All Key Secondary EndpointsPRNewsWire • 08/17/22
Guardant Health and Blueprint Medicines present real-world data identifying EGFR C797X mutation as most common resistance mechanism to osimertinib therapy at IASLC 2022 World Conference on Lung CancerBusiness Wire • 08/08/22
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)PRNewsWire • 08/04/22
Blueprint Medicines Corporation's (BPMC) CEO Kate Haviland on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/02/22
Blueprint Medicines (BPMC) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/02/22
Blueprint Medicines to Report Second Quarter 2022 Financial Results on Tuesday, August 2, 2022PRNewsWire • 07/26/22